Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus | Zendy

Tiziano Allice | Zendy; Alessandro Busca | Zendy; Franco Locatelli | Zendy; Michele Falda | Zendy; Fabrizia Pittaluga | Zendy; Valeria Ghisetti | Zendy

Open Access

Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus

Author(s) -

Tiziano Allice,

Alessandro Busca,

Franco Locatelli,

Michele Falda,

Fabrizia Pittaluga,

Valeria Ghisetti

Publication year - 2009

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkn521

Subject(s) - valganciclovir , cytomegalovirus , transplantation , medicine , immunology , drug resistance , ganciclovir , stem cell , hematopoietic stem cell transplantation , drug , cytomegalovirus infection , foscarnet , intensive care medicine , human cytomegalovirus , virology , herpesviridae , biology , viral disease , pharmacology , virus , genetics , microbiology and biotechnology

Valganciclovir is a well established drug for the management of cytomegalovirus (CMV) infection in haematopoietic stem cell transplantation (HSCT). Data concerning its safety regarding the development of drug resistance are required. The aim of the present study was to retrospectively investigate CMV drug resistance in a group of HSCT patients experiencing relapses of CMV infection after a first-line pre-emptive antiviral therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research